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Abstract
Background: Previous studies and biological mechanisms of carcinogenesis suggest that the steroid
receptor content of benign breast epithelium may be related to breast cancer risk. The objective in this
study was to compare the levels of estrogen receptor-α (ER) and progesterone receptor (PR) in
nonneoplastic breast epithelium between breast cancer cases and biopsy controls.
Methods: Between 1995 and 1997 at two sites (Women's College Hospital in Toronto and Kingston
General Hospital), 667 women who were scheduled for diagnostic excisional breast biopsies completed a
questionnaire providing personal information and agreed to allow analysis of routinely resected tissue.
Histological slides with nonneoplastic epithelium were available for 101 cancer cases and 200 biopsy
controls in Toronto and for 105 cancer cases and 119 controls in Kingston. Nonneoplastic epithelium was
examined with immunohistochemical assays to determine the percent of epithelial cells staining for ER and
PR. Unconditional logistic regression was used to calculate odds ratios (OR) stratified by study site.
Results: The ER content of nonneoplastic tissue was higher in cases than biopsy controls in unadjusted
analyses; after adjustment for age, however, a weak association remained in only one of the study sites.
After adjustment for age, the PR content of nonneoplastic tissue was slightly lower in breast cancer cases
than controls in one study site. Furthermore, this inverse association was confined to women with PR
negative breast cancer in comparison to the controls. No interaction between ER and PR content of
nonneoplastic tissue was observed in relation to the odds of having breast cancer.
Conclusion: The results of this study are consistent with only a slight indication of increased ER levels in
nonneoplastic tissue in breast cancer cases relative to controls. This study contributes to the
understanding of breast cancer by examining both ER and PR in nonneoplastic tissue. Limitations remain,
however, such as the necessity of using as controls women with benign breast changes, difficulties in
selecting the appropriate tissue for analysis, and tissue sampling concurrent to diagnosis.
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Background
Breast cancer risk factors such as early age at menarche,
late age at menopause, postmenopausal hormone ther-
apy, and high body mass index are thought to affect breast
carcinogenesis by increasing the exposure of the breast to
estrogens and other sex hormones [1,2]. Estrogens, partic-
ularly in conjunction with progesterone, are mitogenic to
breast epithelial cells. The resulting proliferation could
increase the probability of mistakes being made in DNA
replication and setting these mistakes as mutations.
Because the effects of estrogens are mediated by the estro-
gen receptors (ER), the magnitude of their effects may be
determined by the level of ER expressed in the breast.
Because breast epithelial cell proliferation is related to
both estrogen and progesterone, and progesterone also
acts through its own receptor [3], levels of the progester-
one receptor (PR) may also be important in breast car-
cinogenesis. In previous case-control studies, Khan and
colleagues observed that the proportion of breast epithe-
lial cells expressing ER was higher in women with breast
cancer than benign breast disease controls [4,5].
We previously conducted a hospital-based case-control
study of the association between breast cancer risk and
breast adipose tissue concentrations of organochlorines
such as polychlorinated biphenyls, DDT, and its metabo-
lite DDE [6]. Because both breast cancer cases and con-
trols had a breast biopsy, we took the opportunity to
examine nonneoplastic sections for ERα and PR to see if
levels of these receptors differed between the breast cancer
cases and controls.
Methods
The methods of the original biopsy case-control study
have been reported in detail elsewhere [6] and the meth-
ods specific to this study will be described in detail here.
The original and extended protocols were approved by the
ethics committees at Women's College Hospital and
Queen's University/Kingston General Hospital and all
subjects provided informed consent.
Subjects
Subjects were women who had a diagnostic breast biopsy
at Women's College Hospital in Toronto or Kingston Gen-
eral Hospital in Kingston between 1995 and 1997.
Because the original study depended on obtaining a sam-
ple of breast adipose tissue in which to measure organo-
chlorines, biopsy controls were chosen. Before biopsy, the
study was presented by the surgeons to all women who
did not have previous cancer or breast implants and were
under the age of 80. After the biopsy, pathology records
were reviewed and all women with in situ or invasive
breast cancer were cases and all women whose biopsy was
negative for malignancy were controls.
Of the 824 eligible women, 667 (80.9%) provided
informed consent and completed a questionnaire that col-
lected information about known and suspected risk fac-
tors that were considered as potential confounders in the
analyses. Mammographic density was also determined in
a subset of 359 women whose mammograms were avail-
able to us for analysis. The mammograms were digitized
and a computer-assisted thresholding program, Cumulus,
allowed separation of the breast area from the back-
ground and dense area from nondense area. Percent dense
area is calculated by dividing the number of pixels repre-
senting dense breast tissue by the total number of pixels in
the breast [7].
Immunohistochemistry on nonneoplastic tissue
Routine practice at both hospitals from which subjects
were recruited was to store surgical specimens from all
diagnostic biopsies. We attempted to locate the stored sec-
tions of nonneoplastic tissue of the 667 subjects who
completed a questionnaire for this study. Stored sections
were located for 561 (84.1%) subjects; because this exten-
sion study started two years following the time when the
last subject had her biopsy and extensive hospital restruc-
turing occurred at one of the study sites (Toronto) during
this time, some slides were unavailable for review. A sec-
tion of nonneoplastic breast tissue from each subject was
chosen by a preliminary review of all of the slides stored.
The absence of nonneoplastic tissue or unsatisfactory
preparation of slides prevented the analysis of the tissue of
36 subjects. Thus, steroid receptor levels in nonneoplastic
tissue were determined for 206 cases and 319 controls.
Tissue sections were first evaluated by hematoxylin and
eosin staining to determine if nonneoplastic epithelium
was present to continue with steroid receptor studies. The
slides chosen had nonneoplastic tissue including a spec-
trum from atrophic, largely fibrous or fatty breast stroma
with only scattered ducts and a minor epithelial compo-
nent to breast tissues containing large numbers of well
formed terminal duct lobular units. In between the two
ends of this spectrum was a range of fibrocystic changes,
mainly microscopic cysts, lobular unfolding, apocrine
metaplasia, and occasional ductal hyperplasia. Rarely the
sections of nonneoplastic tissue included a few ducts
exhibiting ductal carcinoma in situ, but more frequently,
the sections showed a fibroadenoma with a small rim of
normal breast tissue around it. Histology apparent on the
slide was noted.
Steroid receptors were determined using standard immu-
nohistochemical techniques; slides at each site were
stained no more than two weeks after being cut at the clin-
ical pathology departments of the respective hospitals due
to feasibility. Briefly, 5 μm sections were treated with 3%
hydrogen peroxide solution and washed with distilledBMC Cancer 2008, 8:130 http://www.biomedcentral.com/1471-2407/8/130
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water. Slides were then microwaved to retrieve the anti-
body-binding epitope of the antigen and treated with
casein solution (0.5%) and drained. The slides were then
sequentially treated and incubated with the primary anti-
body, biotinylated secondary link antibody, and peroxi-
dase-conjugated streptavidin. Slides were developed in
stable DAB and counterstained with hematoxylin stain.
Differences in the procedures at each hospital include that
the staining procedures were automated on a Ventana ES
system in Kingston but done manually in Toronto, and
the primary antibody against the ER, 6F11, was supplied
by Ventana in Kingston and by Novocastra in Toronto,
and the primary antibody against PR was 1A6 supplied by
Ventana in Kingston and 636 supplied by Dako in
Toronto.
The level of receptors was scored as the percent of immu-
nostained epithelial cell nuclei. An experienced patholo-
gist with expertise in breast pathology (SKS) assessed
sections at 400× magnification under a light microscope.
Although immunohistochemical staining expression was
examined across the entire slides including all ducts and
lobules, only the nonneoplastic tissue without fibrocystic
changes on the slides was scored. The percent of cells
staining positively for the receptors was scored within cat-
egories: < 1, 1–5, 6–10, 11–33, 34–67, and >67. The
pathologist was blind to case-control status.
Tumor characteristics
Levels of ER and PR within the tumors of the cases had
been determined by one or both of immunohistochemis-
try or enzyme immunoassay in each hospital as part of the
routine clinical practice. Using the immunohistochemical
assay, tumors were classified as positive if more than 10%
of the cells showed nuclear staining for the receptor. Using
the enzyme immunoassay, tumors were classified as posi-
tive if the concentration of receptor was greater than 10
fmol/mg cytosolic protein. Cases who were positive by at
least one assay were considered to have positive receptor
status [8]. We obtained the information on ER and PR
within the tumors of the cases from the pathology reports.
Statistical analyses
Because of the differences at each site in the preparation of
the nonneoplastic tissue and the immunohistochemical
staining, and the differences in the distribution of the ERs
by study site that were not explained by case-control sta-
tus, menopausal status and age, analyses were also con-
ducted separately for each site. Subjects with receptor
results were compared to subjects without receptor results
with respect to covariates. Among the subjects with expo-
sure measurements, frequencies (categorical variables)
and means with standard deviations (continuous varia-
bles) of the variables were examined.
The association between ER and PR content of nonneo-
plastic tissue and breast cancer status was examined by
calculating odds ratios (ORs) using multivariable logistic
regression; this approach is consistent with other studies
and allows direct comparison [4,5]. The level of steroid
receptors in nonneoplastic tissue was scored in six catego-
ries, but adjacent categories were combined such that at
least ten cases and ten controls were in each category. Var-
iables considered as covariates derived from the question-
naire included age (continuous), site (Toronto, Kingston),
menopausal status (pre, post), parity (no, yes), lactation
duration (continuous), age at first pregnancy (<20, 20–
24, 25–29, > = 30, nulliparous), age at last pregnancy
(<25, 25–29, 30–34, > = 35, nulliparous), age last breast
fed (never, <30, ≥ 30 years), family history (no, breast can-
cer in first or second degree relative), body mass index
(continuous), fat intake (continuous), energy intake (con-
tinuous), alcohol intake (<1, ≥ 1 drink per week), current
smoking (no, yes), cumulative smoking (continuous),
and current hormone use (no, yes). Subjects who reported
that their menstrual periods had stopped permanently
were classified as postmenopausal. However, six subjects
who had a hysterectomy in the absence of bilateral
oophorectomy and were under the mean age of meno-
pause of subjects having a natural menopause (49 years)
were reclassified as premenopausal. All ORs were adjusted
for age, but no other covariate caused the ORs associated
with steroid receptor levels to consistently change more
than 10% when introduced into the age-adjusted model
and thus, were not included in the models. The confound-
ing effect of mammographic density, which had missing
values for large numbers of subjects, was examined within
the subset of subjects with this measure and was found to
be nil.
Sensitivity analyses were done to examine if exclusion of
cases with carcinomas in situ from the case group, controls
with hyperplasia with atypia, subjects who were currently
using exogenous hormones, premenopausal women, or
subjects with no terminal duct lobular units apparent on
the slide had an effect on the conclusions from the main
analysis. Polytomous logistic regression was used to esti-
mate the association between ER and PR levels in nonne-
oplastic tissue and both ER positive breast cancer and ER
negative breast cancer relative to the control group. A like-
lihood ratio test was performed to evaluate the signifi-
cance of the ER and PR levels in nonneoplastic tissue in a
logistic model comparing ER positive cases with ER nega-
tive cases. The significance of this test indicated if hetero-
geneity existed in the associations between ER and PR
levels in nonneoplastic tissue and risk of ER-positive and
ER-negative breast cancers. Analyses initially were done
separately for ER and PR in nonneoplastic tissue, and then
they were included in the same model to examine
whether they interacted with one another in their associa-BMC Cancer 2008, 8:130 http://www.biomedcentral.com/1471-2407/8/130
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tion with breast cancer status. For these analyses, PR was
dichotomized (<5%, ≥ 5%) and the two uppermost cate-
gories for ER were collapsed to ensure sufficient numbers
in the cells for the analysis. All analyses were done using
SAS (SAS Institute, Cary, NC, USA). A p < 0.05 was used
to indicate statistical significance.
Results
When the 206 cases and 319 controls, the subset of sub-
jects with measurements for ER and PR in nonneoplastic
tissue, were compared with the total group of 267 cases
and 400 controls who had completed a questionnaire, it
was found that more subjects from Toronto (27.1%) had
missing receptor results than from Kingston (11.8%); this
was observed for both cases and controls. Characteristics
of the cases and controls included in this analysis with
respect to covariates are shown in Table 1. In both study
sites, cases tended to be older than controls, have a
slightly higher fat intake, and have smoked more ciga-
rettes. A lower proportion of cases than controls was pre-
menopausal, had never breast fed, reported current use of
exogenous hormones, had a family history of breast can-
Table 1: Characteristics of cases and controls, by study site
Toronto Kingston
Characteristic Controls (n = 200) Cases (n = 101) Controls (n = 119) Cases (n = 105)
Age, mean (SD), y 44.9 (9.6) 54.3 (11.4) 56.1 (11.8) 60.6 (11.4)
Breast feeding, mean (SD), months 5.7 (10.2) 5.3 (9.1) 6.5 (15.9) 6.5 (9.5)
Body mass indexa, mean (SD), kg/m2 23.3 (3.9) 24.3 (4.3) 25.7 (4.5) 25.4 (4.7)
Energy intakea, mean (SD), kcal/day 957 (385) 991 (307) 981 (385) 1121 (374)
Fat intakea, mean (SD), g/day 33.3 (14.8) 35.1 (12.8) 37.4 (17.9) 43.3 (16.3)
Smokinga, mean (SD), pack-years 7.8 (12.9) 9.0 (13.2) 10.9 (15.9) 13.4 (17.1)
Mammographic densitya, mean (SD), % 41.0 (18.7) 35.8 (16.2) 26.5 (17.6) 26.0 (17.3)
Menopausal status, n (%) 54 (27.0) 59 (58.4) 79 (66.4) 81 (77.1)
Gravid, n (%) 149 (74.5) 78 (77.2) 106 (89.1) 93 (88.6)
Age last breast fed, n (%)
never 105 (52.5) 45 (44.6) 65 (54. 6) 46 (43.8)
<30 42 (21.0) 24 (23.8) 32 (26.9) 26 (24.8)
≥30 53 (26.5) 32 (31.7) 22 (18.5) 33 (31.4)
Oral contraceptives at questionnaire, n (%) 12 (6.0) 8 (7.9) 1 (0.8) 1 (1.0)
Hormone therapy at questionnaire, n (%) 26 (23.0) 8 (7.9) 27 (22.7) 10 (9.5)
Family history, n (%) 83 (41.5) 35 (34.7) 41 (34.5) 42 (40.0)
Alcohol consumed >1 drink/weeka, n (%) 103 (52.0) 44 (44.0) 52 (43.7) 37 (35.6)
Current smoking, n (%) 49 (24.5) 18 (17.8) 25 (21.0) 22 (21.0)
Invasive cancer, n (%) - 88 (87.1) - 94 (89.5)
Tumor steroid receptor status, n (%) - -
ER+/PR+ 55 (54.5) 59 (56.2)
ER+/PR- 10 (9.9) 14 (13.3)
ER-/PR+ 7 (6.9) 4 (3.8)
ER-/PR- 24 (23.8) 20 (19.0)
Missing 5 (5.0) 8 (7.6)
Atypical hyperplasia, n (%) 13 (6.5) - 3 (2.5) -
Nonneoplastic cells staining for ER, n (%)
<1% 63 (31.5) 21 (20.8) 3 (2.5) 2 (1.9)
1–5 66 (33.0) 23 (22.8) 13 (12.4) 4 (3.8)
6–10 43 (21.5) 27 (26.7) 27 (22.7) 24 (22.9)
11–33 17 (8.5) 17 (16.8) 37 (31.1) 23 (21.9)
34–66 9 (4.5) 9 (8.9) 28 (23.5) 25 (23.8)
>66 2 (1.0) 4 (4.0) 11 (9.2) 27 (25.7)
Nonneoplastic cells staining for PR, n (%)
<1% 20 (10.0) 22 (21.8) 16 (13.4) 16 (15.2)
1–5 70 (35.0) 27 (26.7) 39 (32.8) 36 (34.3)
6–10 62 (31.0) 31 (30.7) 47 (39.5) 31 (29.5)
11–33 27 (13.5) 12 (11.9) 10 (8.4) 12 (11.4)
34–66 12 (6.0) 9 (8.9) 7 (5.9) 8 (7.6)
>66 9 (4.5) 0 (0.0) 0 (0.0) 2 (1.9)
ER, estrogen receptor; PR, progesterone receptor; SD, standard deviation.aInformation for BMI is missing for 3 subjects, energy, fat and alcohol 
consumption is missing for 4 subjects, cumulative smoking is missing for 4 subjects, and mammographic density is missing for 166 subjects.BMC Cancer 2008, 8:130 http://www.biomedcentral.com/1471-2407/8/130
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cer, and consumed more than one alcoholic beverage per
week. A higher percentage of epithelial cells stained posi-
tively for ER among cases than controls. Among controls,
the ER level in nonneoplastic tissue was associated with
age (Spearman correlation, rs = 0.49, p < 0.0001). After
adjustment for age, fat intake was the only covariate asso-
ciated with ER level (Spearman correlation, rs = 0.14, p =
0.01). Among controls, the PR level in nonneoplastic tis-
sue was not associated with age or any other covariate
after age adjustment.
Association of ER in nonneoplastic tissue and breast 
cancer status
The crude and age-adjusted ORs for the association
between ER levels in nonneoplastic tissue and breast can-
cer status overall and stratified by study site are shown in
Table 2. The crude ORs suggest a positive association
between the percentage of cells staining for ER staining in
nonneoplastic tissue and breast cancer status in both sites.
Age, however, was a strong confounder due to its associa-
tion with case status (t-test p < 0.005) and with ER levels.
When age was taken into account, the ORs were attenu-
ated toward the null value. The OR for the uppermost cat-
egory of ER (>66% positively staining cells) relative to the
lowermost category (<1% cells staining positively)
remained elevated (OR = 2.6; 95% confidence interval
(CI): 1.1–6.2) but no other OR was significantly different
from the null. This was largely due to the influence from
the Kingston site. The association between ER and breast
cancer status was not different by menopausal status (p-
value for interaction = 0.50). Exclusion of cases with car-
cinoma in situ only, controls with atypical ductal hyper-
plasia, or subjects whose slides contained no TDLUs
changed the results for each site very little. When subjects
who reported taking exogenous hormones were excluded,
the ORs increased slightly for Toronto but were attenuated
slightly to the null for Kingston.
The percentage of nonneoplastic epithelial cells staining
positively for ER was not significantly differentially
related to ER positive breast cancer status as compared to
ER negative breast cancer (p = 0.72), nor was it signifi-
cantly differentially related to PR positive breast cancer
status as compared to PR negative breast cancer (p = 0.44;
results not shown). Note, however, that the number of ER
negative cancer cases (n = 55) or PR negative cancer cases
(n = 68) in our study was small and the power to detect
differences was low.
Association of PR in nonneoplastic tissue and breast 
cancer status
The crude and age-adjusted ORs for the association
between PR levels in nonneoplastic tissue and breast can-
cer status overall and stratified by study site are shown in
Table 3. Among subjects from Toronto, the crude ORs sug-
gest a slightly inverse association between the percentage
of PR staining cells in nonneoplastic tissue and breast can-
cer status; this was not observed in the subjects from King-
ston. When age was taken into account, the ORs were only
slightly attenuated toward the null value. The associations
did not differ significantly by menopausal status (p-values
for interaction ≥ 0.06). Exclusion of cases with carcinoma
Table 2: Association between ER in nonneoplastic tissue and breast cancer status, by study site
Site Controls Cases
Cells staining for ER N (%) N (%) Crude OR (95% CI) Age-adjusted OR (95% CI)
Both
<1% 66 (20.7) 23 (11.2) 1.0 1.0
1–5 79 (24.8) 27 (13.1) 1.0 (0.5–1.9) 0.9 (0.5–1.7)
6–10 70 (21.9) 51 (24.8) 2.1 (1.2–3.8) 1.5 (0.8–2.8)
11–33 54 (16.9) 40 (19.4) 2.1 (1.1–4.0) 1.3 (0.7–2.5)
34–66 37 (11.6) 34 (16.5) 2.6 (1.4–5.1) 1.4 (0.7–2.8)
>66 13 (4.1) 31 (15.0) 6.8 (3.1–15.3) 2.6 (1.1–6.2)
Toronto
<1% 63 (31.5) 21 (20.8) 1.0 1.0
1–5 66 (33.0) 23 (22.8) 1.0 (0.5–2.1) 0.9 (0.5–2.0)
6–10 43 (21.5) 27 (26.7) 1.9 (0.9–3.8) 1.2 (0.6–2.5)
11–33 17 (8.5) 17 (16.8) 3.0 (1.3–6.9) 1.4 (0.6–3.6)
>33 11 (5.5) 13 (12.9) 3.5 (1.4–9.1) 1.4 (0.5–3.9)
Kingston
≤10% 43 (37.6) 30 (28.6) 1.0 1.0
11–33 37 (31.1) 23 (21.9) 0.9 (0.4–1.8) 0.9 (0.4–1.7)
34–66 28 (23.5) 25 (23.8) 1.3 (0.6–2.6) 1.1 (0.5–2.4)
>66 11 (9.2) 27 (25.7) 3.5 (1.5–8.2) 2.7 (1.1–6.6)
CI, confidence interval; ER, estrogen receptors; OR, odds ratio.BMC Cancer 2008, 8:130 http://www.biomedcentral.com/1471-2407/8/130
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in situ only, controls with atypical ductal hyperplasia, sub-
jects whose slides contained no TDLU, or subjects using
exogenous hormones would not change the conclusions
made from these analyses.
The percentage of nonneoplastic epithelial cells staining
positively for PR was not significantly differentially
related to ER positive breast cancer status as compared to
ER negative breast cancer (p = 0.67). It was, however, sig-
nificantly differentially related to PR positive breast cancer
status as compared to PR negative breast cancer among
subjects from Toronto (p = 0.03). Although PR levels in
nonneoplastic tissue were not related to PR positive breast
cancer status, levels of PR in nonneoplastic tissue above
1% were associated with reduced odds of having PR neg-
ative breast cancer status (results not shown). The same
trend was seen among subjects from Kingston, but it was
not statistically significant (p = 0.19).
Interaction between ER and PR in nonneoplastic tissue 
and breast cancer status
Levels of ER and PR in nonneoplastic breast tissue were
positively correlated. The partial Spearman correlation
(adjusted for age) was rs = 0.36 in Toronto controls, rs =
0.42 in Kingston controls, rs = 0.50 in Toronto cases, and
rs = 0.65 in Kingston cases. In Kingston, the odds of being
a breast cancer case with respect to ER levels was qualita-
tively higher in women in whom PR levels were higher
(Table 4). The interaction, however, was not statistically
significant in either site (p > 0.34).
Discussion
After age was taken into account, very little association
remained between ER levels in nonneoplastic tissue and
breast cancer status. The odds of having the highest level
of ER were higher in breast cancer cases than biopsy con-
trols only in Kingston, one of our two study sites. Some
indication of an inverse association between PR levels in
nonneoplastic tissue and breast cancer status was
observed among subjects from Toronto, which was largely
because of the association of PR levels with PR negative
breast cancers; no association between PR levels in nonne-
oplastic tissue and breast cancer status was observed
among subjects from Kingston.
Table 3: Association between PR in nonneoplastic tissue and breast cancer status, by study site
Site Controls Cases
Cells staining for PR N (%) N (%) Crude OR (95% CI) Age-adjusted OR (95% CI)
Both
<1% 36 (11.3) 38 (18.5) 1.0 1.0
1–5 109 (34.2) 63 (30.6) 0.5 (0.3–1.0) 0.7 (0.4–1.2)
6–10 109 (34.2) 62 (30.1) 0.5 (0.3–0.9) 0.8 (0.4–1.4)
>10 65 (20.4) 43 (20.9) 0.6 (0.3–1.1) 0.7 (0.4–1.3)
Toronto
<1% 20 (10.0) 22 (21.8) 1.0 1.0
1–5 70 (35.0) 27 (26.7) 0.4 (0.2–0.7) 0.5 (0.2–1.1)
6–10 62 (31.0) 31 (30.7) 0.5 (0.2–1.0) 0.9 (0.4–2.0)
>10 48 (24.0) 21 (20.8) 0.4 (0.2–0.9) 0.4 (0.2–1.0)
Kingston
<1% 16 (13.4) 16 (15.2) 1.0 1.0
1–5 39 (32.8) 36 (34.3) 0.9 (0.4–2.1) 1.0 (0.4–2.4)
6–10 47 (39.5) 31 (29.5) 0.7 (0.3–1.5) 0.8 (0.3–1.8)
>10 17 (14.3) 22 (20.9) 1.3 (0.5–3.3) 1.4 (0.5–3.6)
CI, confidence interval; OR, odds ratio; PR, progesterone receptor.
Table 4: Joint association between both ER and PR in 
nonneoplastic tissue and breast cancer status, by study site
Site Cells staining for PR
Cells staining for ER ≤5% >5%
Both
<1% 1.0 1.0
1–5 0.5 (0.2–1.3) 1.8 (0.6–5.9)
6–10 1.4 (0.6–3.3) 1.9 (0.6–5.7)
>10 1.1 (0.5–2.5) 2.6 (0.9–7.6)
p(interaction) = 0.29
Toronto
<1% 1.0 1.0
1–5 0.6 (0.2–1.6) 1.9 (0.6–6.2)
6–10 1.4 (0.5–3.9) 1.3 (0.4–4.5)
>10 1.6 (0.4–5.7) 1.6 (0.4–5.9)
p(interaction) = 0.34
Kingston
≤10% 1.0 1.0
11–33 0.9 (0.3–2.6) 1.2 (0.4–3.9)
>33 1.1 (0.4–2.8) 3.1 (0.9–10.3)
p(interaction) = 0.69
ER, estrogen receptor; PR, progesterone receptor.BMC Cancer 2008, 8:130 http://www.biomedcentral.com/1471-2407/8/130
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Khan et al. [4,5] have found increased ER levels in benign
tissue in breast cancer cases than controls even after
adjusting for age. In comparison to our unadjusted analy-
ses, they observed an increase in risk for ER levels between
1% and 5% relative to less than 1% but no further
increases in risk with ER levels beyond 5% [4]. The unad-
justed ORs in our study did not increase until higher levels
of ER in nonneoplastic tissue were reached. Khan et al. [4]
also did not see as strong confounding by age as we did,
although in their study the mean age of cases and controls
differed by 13 years and age was significantly correlated
with ER levels (r = 0.20). In an early study, Ricketts et al.
found that mean ER levels determined by enzyme immu-
noassay were higher in breast cancer cases than age-
matched controls [9]. Another early study found higher
levels of ER in tissue taken from a quadrant opposite to a
breast lesion in women having mastectomies as compared
to tissue taken from reduction mammoplasties, but the
ages of these groups were unknown [10]. A nested case-
control study done among patients who had benign
breast biopsies showing usual ductal hyperplasia found
that patients who developed cancer at least six months
after this time had nonsignificantly higher median expres-
sion of ER in normal tissue and a significantly higher
expression of ER in the hyperplastic lesion than age-
matched controls who did not develop cancer in the fol-
low-up period [11]. A recent study showed that ER levels
were nonsignificantly higher in women with fibroadeno-
mas than women with either a strong family history with-
out known BRCA  mutations or a previous history of
cancer suggesting that women at high risk of developing
breast cancer do not have higher ER expression than
women who are not at higher risk of breast cancer [12].
Differences in the methods of determining ER levels in
nonneoplastic tissue likely contribute to discrepancies
between this study and others, and between the sites in
this study. Variation in the distribution of ER in nonneo-
plastic tissue is apparent among many studies [11,13-17].
We found differences in the distribution of ER levels
between our study sites even when using similarly proc-
essed tissue (formalin-fixed, paraffin-embedded), using
the same monoclonal antibody (6F11), having a single
pathologist to score all the sections, and statistically con-
trolling for age, case-control status and menopausal sta-
tus. Other factors on which information was not available
may have contributed to these differences: a delay in fixa-
tion, shorter or longer fixation time, and delay of staining
prepared slides are all thought to reduce immunoreactiv-
ity with many ER antibodies [18,19]. The distribution of
ER was lower in Toronto than Kingston and some degra-
dation of the ER possibly occurred at this site. If the distri-
bution was shifted downward similarly between cases and
controls, a difference should still be seen if there was one.
The difference by study site in the distribution of ER levels
is a main limitation of this study; it is illustrative of differ-
ences that may have occurred between studies but have
not been identified because individual studies have been
conducted at a single site. If exquisite attention is paid to
maintaining strict and unchanging assay methods for all
samples within a study, and recording information about
parameters (eg. time to fixation, fixation time) that can-
not be controlled so adjustment for their effects can be
made in the analysis, the observed effect may be stronger
with less misclassification and it will be known more
clearly if ER degradation occurs differently between cases
and controls. The results from most studies are consistent
with ER levels in nonneoplastic tissue being increased in
women with breast cancer relative to controls.
Two interpretations of a difference in steroid hormone
receptor levels in nonneoplastic breast tissue between
breast cancer cases and benign breast disease controls
could be that steroid hormone receptor levels increase the
risk of developing breast cancer, or that steroid hormone
receptor levels are influenced by adjacent tumors or other
pathology. If steroid hormone receptor levels increase the
risk of breast cancer, two interrelated mechanisms could
be in operation. The first mechanism is that breast tissue
with higher expression of ER could be more susceptible to
the mitogenic effects of estrogens. Variation in the expres-
sion of ER may be due to differences in the level of differ-
entiation of the glandular elements in the breast tissue
[20], the number of intermediate cells capable of sending
mitogenic paracrine signals to the epithelial cells in
response to estrogens [21] and/or preneoplastic changes
in the breast. Variation in the expression of ERs may have
a genetic component but may also be influenced by preg-
nancy and lactation history. The second mechanism could
involve ER levels being a marker of current estrogen levels;
estrogen levels themselves could increase breast cancer
risk via ER-dependent stimulation of proliferation or via
DNA damage through ER-independent mechanisms by
various estrogen metabolites [1,2]. Estrogen receptor lev-
els, however, are negatively regulated by current levels of
estrogens [3] and were found to be consistently related to
only one marker of current estrogens in both sites in this
study – age. Analyses that control for current estrogen lev-
els measured in blood or breast tissue would help to clar-
ify if women whose breast tissues have a tendency to
express more ER in the background of a given level of
estrogen would be at greater risk for developing a cancer.
In this vein, Khan et al. 1999 [22] found that ER levels in
nonneoplastic tissue were negatively associated with
serum estradiol levels only among benign controls, but
not in breast cancer cases. On the other hand, Bhandare et
al. 2005 [16] found that estradiol levels in ductal lavage
supernatant were not associated with the ER labeling of
the epithelial cells in women without cancer (but who didBMC Cancer 2008, 8:130 http://www.biomedcentral.com/1471-2407/8/130
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have a high Gail risk score for cancer), but that estrone sul-
phate levels were positively associated with ER labeling.
The PR gene is responsive to estrogen [3] and PR levels
could be considered an indicator of the current activity of
estrogens in the breast tissue – a concatenation of the lev-
els of ER and estrogen. Few studies have examined the
association between PR levels in nonneoplastic tissue and
breast cancer risk. Whereas the early study by Netto et al.
[10] found that cases had a higher distribution of PR than
reduction mammoplasty controls, Khan et al. [4] found
no significant difference between cases and controls with
respect to the mean proportion of nonneoplastic cells
staining for PR. We have found a reduced risk of breast
cancer associated with PR levels in nonneoplastic tissue in
only one study site. We had also hypothesized that
women who had higher levels of PR may be at greater risk
of breast cancer due to ER levels than women who had
lower levels of PR because they may be the women whose
breast tissues have higher exposure to estrogen. We only
found a qualitative indication of this in one of our study
sites; this finding, however, was not statistically signifi-
cant, could be due to chance, and should be investigated
in other studies. Another analysis that we performed sup-
ports this idea – the correlation between ER and PR in
nonneoplastic tissue was higher in cases than controls at
both sites. This suggests that for a given level of ER, the
background of estrogen elicited a response, PR expression,
to a greater extent in the cases than the controls. This
could be due to a higher estrogen background in the cases
than in the controls, or that cases have disregulated down-
regulation of the ER with the estrogen-dependent expres-
sion of PR.
In this study and others, steroid hormone receptors may
have been different between cases and controls because
they could be affected by a paracrine effect from adjacent
tumors or pathologies. For example, cases could have a
higher level of background estrogen around the tissue in
the slides used in this study because tumor tissue is known
to express estrone sulphatase, 17β-hydroxysteroid dehy-
drogenase, and aromatase, enzymes involved in estrogen
biosynthesis [23]. Some studies have observed that the
levels of aromatase and estrone sulphatase are higher in
ER+/PR+ tumors than in ER-/PR- tumors [24,25], suggest-
ing that the surrounding tissues of these tumors should
differ in their ER and PR levels; this was not observed in
this study but it has been in other studies [26,26-28]. The
levels of enzymes involved in estrogen synthesis are also
increased in benign breast conditions such as fibroadeno-
mas [29]. Ideally, a study should be done in which steroid
receptors were measured before the development of can-
cer.
Our study had some limitations in addition to the differ-
ences in ER levels by study site. Out of necessity, our con-
trols were women who had a biopsy because they were
suspected of harbouring a breast tumor; many had some
form of benign breast changes on this biopsy but exclu-
sion of those with a lesion associated with a much higher
risk of breast cancer did not change conclusions from
these results. We had a small sample size that reduced the
power of subgroup analyses of interest (eg. by menopau-
sal status). Steroid receptor expression and other features
such as extent of differentiation and involution vary by
the location of the epithelial cells (eg. duct versus lobule
and from lobe to lobe) [14]; ER levels, however, have
been shown to be quite consistent over time [30]. Meas-
urement of other factors such as proliferation, age-related
involution, ER-β, PR-A and PR-B separately, and coexpres-
sion of these factors may give a more complete picture of
what makes the breast tissues of some women more sus-
ceptible to carcinogenesis than the tissues of other
women.
Conclusion
The results of this study and others are not inconsistent
with a small increase in risk of breast cancer associated
with ER levels in nonneoplastic tissue. Further work on
the meaning of the role of ER-expressing cells in the breast
combined with an attempt to control for the level of estro-
gens to which the cells were exposed when sampled will
help to clarify this question.
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